Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
20 mars 2025 02h00 HE
|
Pharming Group N.V.
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients...
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
19 mars 2025 16h05 HE
|
Alumis Inc.
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
19 mars 2025 09h28 HE
|
GENENTA SCIENCE SPA
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
19 mars 2025 08h30 HE
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
18 mars 2025 16h29 HE
|
Silexion Therapeutics Corp
Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences
18 mars 2025 14h25 HE
|
BioAegis Therapeutics
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will...
ZHITTYA GENESIS MEDICINE ANNOUNCES: DR. JACK JACOBS, PRESIDENT, TO RECEIVE NEVADABIO HONOR FOR PARKINSON’S DISEASE BREAKTHROUGH
18 mars 2025 10h00 HE
|
Zhittya Genesis Medicine Inc
Parkinson's disease reversed for 200 human medical research patients
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
18 mars 2025 09h00 HE
|
Oribiotech Ltd
Oribiotech Ltd. (Ori), announced the launch of its Preferred Partner Network (PPN), bringing together top AMCs and CDMOs.
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
13 mars 2025 18h07 HE
|
Cellectis Inc.
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
13 mars 2025 16h01 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update